Literature DB >> 8001209

Neuromuscular effects of vecuronium and neostigmine in Montreal and Paris.

Y Salib1, J Frossard, B Plaud, B Debaene, C Meistelman, F Donati.   

Abstract

The potency of vecuronium was reported to be greater in Montréal than in Paris. This study was designed to determine whether there were differences in onset, duration, and reversibility with neostigmine between both centres. Twenty ASA I or II adults (ten men, ten women), aged 18-65 yr were studied in each of the two cities, during a standard thiopentone-fentanyl-nitrous oxide (60-70%) - isoflurane 0.5% end-tidal anaesthetic. Train-of-four stimulation was applied every 20 sec to the ulnar nerve at the wrist and the force of contraction of the adductor pollicis muscle was measured. Vecuronium, 0.1 mg.kg-1, was given as a bolus, and neostigmine, 0.04 mg.kg-1, was administered, with atropine 0.02 mg.kg-1, at 25% first twitch height recovery. Onset time to maximum blockade was (mean +/- SD) 3.9 +/- 1.3 min in Paris vs 4.5 +/- 1.3 min in Montréal (NS). Duration from injection to 25% first twitch recovery was shorter (28.5 +/- 6.8 min) in Paris than in Montréal (39.1 +/- 7.3 min) (P < 0.0001). Time from injection of neostigmine to a train-of-four ratio of 70% was not different in Paris (6.3 +/- 2.2 min) from Montréal (5.6 +/- 1.9 min). It is concluded that the duration of an "intubating" dose of vecuronium is longer in Montréal, but, when given at 25% first twitch recovery, neostigmine has the same efficacy in Montréal as in Paris.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8001209     DOI: 10.1007/BF03010933

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  20 in total

1.  Comparison of large dose of vecuronium with pancuronium for prolonged neuromuscular blockade.

Authors:  K Rørvik; P Husby; L Gramstad; J S Vamnes; L Bitsch-Larsen; M E Koller
Journal:  Br J Anaesth       Date:  1988-08       Impact factor: 9.166

2.  Onset and recovery of atracurium and suxamethonium-induced neuromuscular blockade with simultaneous train-of-four and single twitch stimulation.

Authors:  M J Curran; F Donati; D R Bevan
Journal:  Br J Anaesth       Date:  1987-08       Impact factor: 9.166

3.  A comparison of the effects of suxamethonium and tubocurarine in patients in London and New York.

Authors:  R L Katz; J Norman; R F Seed; L Conrad
Journal:  Br J Anaesth       Date:  1969-12       Impact factor: 9.166

4.  Vecuronium and prolonged neuromuscular blockade in postpartum patients.

Authors:  C E Camp; J Tessem; J Adenwala; T H Joyce
Journal:  Anesthesiology       Date:  1987-12       Impact factor: 7.892

5.  Effects of residual concentrations of isoflurane on the reversal of vecuronium-induced neuromuscular blockade.

Authors:  M J Baurain; A A d'Hollander; C Melot; B S Dernovoi; L Barvais
Journal:  Anesthesiology       Date:  1991-03       Impact factor: 7.892

6.  Distribution, elimination, and action of vecuronium in the elderly.

Authors:  C A Lien; R S Matteo; E Ornstein; A E Schwartz; J Diaz
Journal:  Anesth Analg       Date:  1991-07       Impact factor: 5.108

7.  Comparison of vecuronium- and atracurium-induced neuromuscular blockade in postpartum and nonpregnant patients.

Authors:  K S Khuenl-Brady; J Koller; P Mair; F Pühringer; G Mitterschiffthaler
Journal:  Anesth Analg       Date:  1991-01       Impact factor: 5.108

8.  Onset and duration of neuromuscular blockade following high-dose vecuronium administration.

Authors:  B Ginsberg; P S Glass; T Quill; D Shafron; K D Ossey
Journal:  Anesthesiology       Date:  1989-08       Impact factor: 7.892

9.  The influence of atropine dose on recovery from vecuronium-induced neuromuscular blockade.

Authors:  M J Baurain; B S Dernovoi; A A d'Hollander; L Barvais
Journal:  Anesthesiology       Date:  1992-07       Impact factor: 7.892

10.  Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient.

Authors:  A E Schwartz; R S Matteo; E Ornstein; J D Halevy; J Diaz
Journal:  Anesth Analg       Date:  1992-04       Impact factor: 5.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.